Suicidal Ideation Suicidal Thoughts Suicidal Feelings Suicidal Impulses Suicide Ideation Suicidal Thoughts Committing Suicide Suicide Anti-Suicide Anti-Suicide remedy Social Phobia General Anxiety Self-Consciousness Reoccurring Thoughts Imposter Syndrome General Anxiety Disorder Post Traumatic Stress Disorder PTSD Panic Paranoia Low Self-esteem Low Self-Confidence Negative Self-Image Negative Thinking Depression Worry, Fretting Anxious Thoughts Anxious Fear of People
Conditions
Interventions
The flower essence formula used in this trial is a safe, non-herbal, proprietary blend of 12 healing codes
(frequency imprints or frequency signatures) from 12 specific flower essences.
These healin
s song or melody, completely unique to that particular plant.
We then recorded these sounds or songs and permanently embedded them into 100% pure pharmaceutical-grade cane sugar pellets (2mm in dia
the 9 Solfeggio frequencies (174 Hz, 285Hz, 396Hz, 417Hz, 528Hz, 639 Hz, 741Hz, 852Hz, 963Hz, and 963 Hz)
and Bio-geometry frequency constructs (that is: all shapes or forms vibrate at different frequencies).
Participants were instructed to take four pellets
Flower Essences,Flower essence placebo remedy
Sponsors
Prescott University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Participants Eligibility Criteria: 1. U.S. and Canadian adults, 2. who had a history of childhood trauma; 3. and who had been suffering from Suicidal Ideation for at least one full year.
Exclusion criteria
Exclusion criteria: Exclusion Criteria: People who have 1. known major physical illnesses (cancer, heart disease, autoimmune diseases, etc.); 2. who have been diagnosed with a mental illness such as psychosis or schizophrenia; 3. who engage in extreme self-harm practices or who have extreme suicidal tendencies; 4. who have used psychoactive drugs, hallucinogens (including: LSD, PCP, Psilocybin, Salvia, Ecstasy, Ayahuasca, mescaline or similar compounds), as well as amphetamines, barbiturates, within three months prior to enrollment; 5. who have been confirmed clinically depressed; 6. who have abused alcohol or drugs six months (or more) prior to enrollment; 7. who were experiencing mild to severe symptoms of any FDA approved or unapproved vaccine, six months after taking it; 8. who were not participating in any other clinical trial involving any investigative product six months prior to enrollment in the study or planned participation in another clinical trial within one year following enrollment; 9. who had cognitive impairment so substantial as to interfere with an understanding of the concept of suicide, suicidal ideation, and/or suicidal behavior. 10. who suffered from severe cognitive impairment due to Alzheimers disease; 11. who suffered from dementia, mental retardation, or autism.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Suicidal Ideation Reduction and/or Elimination in Study Subjects Within 30 days following the completion of the trial Suicide Behaviors Questionnaire-Revised (SBQ-R), Beck Scale for Suicide Ideation (SSI), Beck Hopelessness Scale (BHS), Columbia-Suicide Severity Rating Scale, The Patient Health Questionnaire (PHQ-9) | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction and/or Elimination of Childhood Trauma, Including the Memory of Said Trauma Within 30 days following the completion of the trial Trauma-related Cognitions and Beliefs scale (TRCS), Structured Trauma-Related Experiences and Symptoms Screener (STRESS), | — |
Countries
United Kingdom
Contacts
Public ContactSky Zelaya
Prescott University
Outcome results
None listed